[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. [The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells]. Biomed Khim; 2005;51(1):48-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells].
  • The influence of modified antineoplaston AS2-1 (with altered ratio of L-phenylalanine and L-glutamine derivatives, "Deglutam") on the activity of glutamine synthetase, glutaminase isoforms in the carcinosarcoma SM-1, tumor weight, per cent of the inhibition of tumor growth and blood impact index was investigated in rats with carcinosarcoma SM-1.
  • The preparation was administered in the dose of 125 mg/kg twice a day for 12 days (on the 7th day after tumor transplantation).
  • Intensive growth of carcinosarcoma SM-1 was accompanied by activtion of the glutamine metabolizing enzymes.
  • The dose-response effect of "Deglutam" on the studied enzymes depended on the mode of preparation administration.
  • The intragastric administration of the preparation caused the same effect on the glutamine metabolizing of SM-1 cells; as it was earlier observed in rat liver.
  • Administration of the modified preparation ANP AS2-1 (containing L-glutamine derivatives) influences regulation of glutamine metabolism in carcinosarcoma SM-1 cells, possibly, due to formation of substrates in the tissues of the tumor-bearing body similar to glutamine.
  • This may explain greater effectiveness of the synthetic preparation on the basis of L-glutamine derivatives rather than the amino acid itself.
  • [MeSH-major] Carcinosarcoma / metabolism. Dipeptides / administration & dosage. Glutamine / administration & dosage. Glutamine / analogs & derivatives. Glutamine / metabolism. Phenylacetates / administration & dosage
  • [MeSH-minor] Animals. Drug Combinations. Male. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. Glutamine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850218.001).
  • [ISSN] 2310-6972
  • [Journal-full-title] Biomedit︠s︡inskai︠a︡ khimii︠a︡
  • [ISO-abbreviation] Biomed Khim
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Dipeptides; 0 / Drug Combinations; 0 / Phenylacetates; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1
  •  go-up   go-down


2. Katzir I, Shani J, Wolf W, Chatterjee-Parti S, Berman E: Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy. Cancer Invest; 2000;18(1):20-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
  • Although 5-fluorouracil (5-FU) is one of the most effective single agents in treating solid tumors, its low effectiveness as a single agent has led to development of a number of modulators intended to enhance its therapeutic effectiveness.
  • The effect of these two drugs on the uptake and the intratumoral metabolism of 5-FU was studied in two rat tumor models using 19F-nuclear magnetic resonance spectroscopy: on excised samples of Walker 256 carcinosarcoma and noninvasively (in vivo) in Novikoff hepatoma.
  • [MeSH-major] Carcinoma 256, Walker / metabolism. Fluorouracil / pharmacokinetics. Liver Neoplasms, Experimental / metabolism. Methotrexate / pharmacology. Trimetrexate / pharmacology
  • [MeSH-minor] Animals. Drug Administration Schedule. Fluorine. Kinetics. Magnetic Resonance Spectroscopy / methods. Male. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. TRIMETREXATE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FLUORINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10701363.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 284SYP0193 / Fluorine; U3P01618RT / Fluorouracil; UPN4ITI8T4 / Trimetrexate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. He YC, Chen JW, Cao J, Pan DY, Qiao JG: Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats. World J Gastroenterol; 2003 Aug;9(8):1795-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the toxicities, biodistribution and anticancer effect of 5-fluorouracil controlled release implant (5-FUCI) on Walker 256 carcinosarcoma cells in Wistar rats.
  • Blank implant was implanted in left lobe of the liver, and rats were treated with saline solution (in group A) or 5-fluorouracil (subcutaneous injection, group B).
  • 5-FUCI was inserted in left lobe of the liver (group C).
  • Experiment 2: on day 6 after Walker-256 carcinosarcoma transplantation in left lobe of the liver, 5-FUCI was implanted in right lobe of the liver (group E) or left lobe (group F), and rats in control group (group D) were inserted blank implant.
  • Histological examination revealed that there were no visible changes in small intestinal mucosa, The concentration of 5-fluorouracil in left lobe of the liver was 9.84, 28, 34 times as much as those of right lobe of the liver, heart and kidney respectively after the implantation in group C.
  • They kept a high level of fluorouracil in left lobe of the liver, ranging from (4.414+/-0.482) % to (7.800+/-0.804) %, for eight weeks.
  • Its antitumor effect on Walker-256 carcinosarcoma is demonstrated.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinosarcoma / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / pathology
  • [MeSH-minor] Animals. Delayed-Action Preparations. Male. Neoplasm Transplantation. Rats. Rats, Wistar. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12918123.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4611546
  •  go-up   go-down


Advertisement
4. Stepensky D, Golomb G, Hoffman A: Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci; 2002 Feb;91(2):508-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone cancer was produced by intratibial inoculation of Walker carcinosarcoma cells, and a model of augmented bone resorption was produced by vitamin D(3) treatment of rats that had undergone thyroidparathyroidectomy.
  • Higher amounts of alendronate were found in bones and in internal organs after bolus drug administration as compared with continuous infusion.
  • Drug effects on plasma calcium levels and on urine calcium excretion were similar in both modes of alendronate administration.
  • [MeSH-minor] Animals. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / urine. Bone Resorption / drug therapy. Calcium / blood. Calcium / urine. Carcinoma 256, Walker / blood. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / pathology. Carcinoma 256, Walker / urine. Drug Administration Schedule. Drug Evaluation, Preclinical / methods. Female. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / urine. Male. Neoplasm Transplantation. Parathyroidectomy. Rats. Rats, Sprague-Dawley. Rats, Wistar. Thyroidectomy. Tibia / pathology

  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:508-516, 2002
  • (PMID = 11835209.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


5. Yang X, Hori T, Fukuda A, Kamimura Y, Hirakawa K, Maeda H, Miyajima H: Malignant myoepithelioma with a squamous epithelial component in the mammary gland of a cynomolgus monkey. Toxicol Pathol; 2003 Sep-Oct;31(5):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic nodules noted in the lung, liver and the gallbladder had the same histological features as the mammary mass.
  • [MeSH-major] Carcinosarcoma / veterinary. Mammary Glands, Animal / pathology. Myoepithelioma / veterinary
  • [MeSH-minor] Animals. Biomarkers, Tumor. Female. Gallbladder / pathology. Immunohistochemistry / veterinary. Liver / pathology. Lung / pathology. Macaca fascicularis


6. Takami M, Idei T, Nakayama Y, Ohta H, Fukai H, Matsumoto H, Togo Y, Sakamoto H, Yamamoto T, Satoh K: [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP]. Gan To Kagaku Ryoho; 2002 Feb;29(2):305-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].
  • Carcinosarcoma of the ovary is a very rare and highly malignant neoplasm that accounts for less than 1% of ovarian neoplasms.
  • We report the case of a 60-year-old woman who had Stage IV advanced heterogeneous ovarian carcinosarcoma with lung and liver metastases.
  • After 7 courses of chemotherapy, the ovarian tumor was obviously reduced, and the lung and liver metastases had disappeared.
  • The current case suggests that combination CPT-11 and CDDP is effective against advanced ovarian carcinosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinosarcoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterotomy. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C: Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer; 2002 Nov-Dec;12(6):749-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group 1 consisted of patients undergoing adjuvant therapy (for initial disease, eight patients; for pelvic recurrence, two patients); Group 2 consisted of patients with advanced disease (locoregional after initial local therapy, five patients; local recurrence, six patients) or metastatic disease (stage IV, four patients; recurrence, 14 patients).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Blood Transfusion. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Carcinosarcoma / secondary. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. France. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Neutropenia. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / mortality. Sarcoma, Endometrial Stromal / secondary. Survival Analysis. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445254.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; DECAV protocol
  •  go-up   go-down


8. Jievaltas M, Stoskuviene L, Petrenkiene V, Barauskas G, Pundzius J: Results of treatment of primary liver cancer at Kaunas University of Medicine Hospital. Medicina (Kaunas); 2004;40(2):127-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of primary liver cancer at Kaunas University of Medicine Hospital.
  • Though the results of treatment of primary liver cancer depend on many circumstances, the opportunity to perform a curative liver resection remains the main point in prognosis on survival.
  • The aim of the study was to examine our first experience in the treatment of liver cancer.
  • From 1996 to 2001 we observed 54 patients with liver cancer: 46 hepatocellular and 6 cholangiocellular carcinomas, 1 malignant carcinoid, and 1 carcinosarcoma.
  • In presence of liver cirrhosis (21 patients, 38.8%) hepatic function was evaluated using Child Pugh classification.
  • Ten patients (18.5%) were radically resected, 12 patients (22.2%) were managed by laparotomy and biopsy, 2 by percutaneous ethanol injections, 1 by trans-ileocolic portal vein embolization + hepatic artery embolization.
  • CONCLUSION. The use of liver resections in patients affected by single or monolateral liver cancer is effective and potentially radical treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / therapy. Hepatectomy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoid Tumor / complications. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Carcinoid Tumor / therapy. Carcinosarcoma / complications. Carcinosarcoma / pathology. Carcinosarcoma / surgery. Carcinosarcoma / therapy. Embolization, Therapeutic. Ethanol / administration & dosage. Female. Hepatic Artery. Humans. Injections, Intradermal. Liver / pathology. Liver Cirrhosis / complications. Liver Function Tests. Male. Middle Aged. Palliative Care. Portal Vein. Postoperative Complications. Prognosis. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15007271.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


9. Tanigawa M, Kimura M, Ichioka M, Saito K, Kimura M: [A case of true pulmonary carcinosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2003 Jul;41(7):496-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of true pulmonary carcinosarcoma].
  • The diagnosis was therefore true pulmonary carcinosarcoma.
  • This recurrent lesion was surgically unresectable, but was regionally controlled with radiotherapy and bronchial arterial infusion of anticancer agents.
  • However, distant metastases occurred to the brain, liver, and small intestine, and digestive tract bleeding also occurred.
  • Liver metastatic lesions were determined to be the adenocarcinomatous component, and the other recurrent or metastatic lesions, except for those in the brain, were all composed of poorly-differentiated sarcomatous tissue.
  • [MeSH-major] Carcinosarcoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Chondrosarcoma / pathology. Humans. Intestinal Neoplasms / secondary. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931680.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Nogusa H, Yamamoto K, Yano T, Kajiki M, Hamana H, Okuno S: Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents. Biol Pharm Bull; 2000 May;23(5):621-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma and tissue distribution of conjugates of carboxymethylpullulan (CMPul) and doxorubicin (DXR), either bound directly or through three types of tetrapeptide spacers, was studied after intravenous injection to rats bearing Walker 256 carcinosarcoma and compared with that of DXR.
  • Disposition characteristics of [3H]CMPul in rats bearing Walker 256 carcinosarcoma indicate that pullulan, which had molecular weight over 50 kDa, is a suitable macromolecular carrier for tumor targeting in cancer chemotherapy by carboxymethylation.
  • CMPul-DXR conjugates were also distributed in the reticuloendothelial organs, such as liver, spleen and bone marrow; however, the tissue concentrations of the conjugates in the heart, lung and muscle were lower than those of DXR.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carcinosarcoma / metabolism. Doxorubicin / pharmacokinetics. Glucans / pharmacokinetics
  • [MeSH-minor] Animals. Carbohydrate Sequence. Female. Male. Mice. Molecular Sequence Data. Peptides / administration & dosage. Peptides / chemistry. Rats. Rats, Wistar. Tissue Distribution. Tritium

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10823676.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucans; 0 / Peptides; 0 / carboxymethylpullulan; 10028-17-8 / Tritium; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK: A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res; 2004 Oct 1;10(19):6512-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other mild to modest adverse effects included nausea, vomiting, liver function tests abnormalities, diarrhea, mucositis, leukopenia, and thrombocytopenia.
  • Major responses did not occur, but durable disease stability was noted in 3 patients, one each with carcinosarcoma of the uterus, pancreas, and ovary, all of whom had experienced disease progression before Col-3 treatment.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Matrix Metalloproteinase Inhibitors. Neoplasms / drug therapy. Tetracyclines / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Area Under Curve. Dose-Response Relationship, Drug. Fatigue / chemically induced. Female. Humans. Male. Matrix Metalloproteinases / metabolism. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475438.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA54174; United States / NCI NIH HHS / CA / CA69853; United States / NCRR NIH HHS / RR / M01 RR01346
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; 0 / Tetracyclines; 0 / tetracycline CMT-3; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


12. Sun DS, Chen JH, Ling R, Yao Q, Wang L, Ma Z, Li Y: Treatment of hepatoma with liposome-encapsulated adriamycin administered into hepatic artery of rats. World J Gastroenterol; 2006 Aug 7;12(29):4741-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of hepatoma with liposome-encapsulated adriamycin administered into hepatic artery of rats.
  • AIM: To observe the therapeutic effects of liposome-encapsulated adriamycin (LADM) on hepatoma in comparison with adriamycin solution (FADM) and adriamycin plus blank liposome (ADM + BL) administered into the hepatic artery of rats.
  • Normal saline, FADM (2 mg/kg), ADM+BL (2 mg/kg), and LADM (2 mg/kg) were injected via the hepatic artery in rats bearing liver W256 carcinosarcoma, which were divided into four groups randomly.
  • CONCLUSION: The anticancer efficacies of adriamycin on hepatoma can be strongly improved by liposomal encapsulation through hepatic arterial administration.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / therapeutic use. Liver Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Hepatic Artery. Injections, Intra-Arterial. Liposomes. Male. Necrosis / pathology. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Drug Deliv Rev. 2001 Aug 23;50(1-2):143-56 [11489337.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1850-2 [11747325.001]
  • [Cites] Arch Pharm Res. 2002 Jun;25(3):229-39 [12135091.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2869-79 [12767102.001]
  • [Cites] Oncologist. 2003;8 Suppl 2:17-24 [13679592.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Feb;308(2):419-25 [14610219.001]
  • [Cites] Biochim Biophys Acta. 1997 Sep 8;1331(2):187-211 [9325441.001]
  • [Cites] Int J Cancer. 1983 Jul 15;32(1):7-12 [6683250.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(1):47-54 [4058077.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4584-7 [3396009.001]
  • [Cites] Sel Cancer Ther. 1990 Fall;6(3):119-27 [2281201.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):262-4 [1346405.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1474-84 [15196530.001]
  • (PMID = 16937449.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC4087843
  •  go-up   go-down


13. Wu HP, Feng GS, Tian Y: Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats. World J Gastroenterol; 2005 Apr 28;11(16):2408-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats.
  • AIM: To study the distribution and stability of antisense oligodeoxynucleotide (ASODN) in Walker-256 cells and their distribution in liver, lung and kidney tissues after being infused alone or mixed with lipiodol via hepatic artery in a rat liver tumor model.
  • Walker-256 carcinosarcoma was transplanted into Wistar rat liver to establish a liver cancer model.
  • 5'-FITC-labeled VEGF ASODN mixed with (mixed group, n = 6) or without (TAI group, n = 6) ultra-fluid lipiodol was administrated via hepatic artery.
  • Frozen samples of liver, lung and kidney tissue were taken from rats after 1, 3 and 6 d, respectively.
  • In vivo experiment, on d 1 and 3 the fluorescence staining in liver was stronger in mixed group than in TAI group and more fluorescence could be detected in lung and kidney in TAI group than in mixed group.
  • ASODN could be seen in cancer cells and normal hepatic cells.
  • In mixed group, ASODN was mainly distributed in liver tumor tissues.
  • ASODN mixed with lipiodol infusion via hepatic artery can be used in the treatment of HCC.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Contrast Media / pharmacokinetics. Iodized Oil / pharmacokinetics. Liver Neoplasms / drug therapy. Oligodeoxyribonucleotides, Antisense / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Fluorescein-5-isothiocyanate / pharmacokinetics. Fluorescent Dyes / pharmacokinetics. Hepatic Artery. Male. Neoplasm Transplantation. Rats. Rats, Wistar. Specific Pathogen-Free Organisms. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832409.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorescent Dyes; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Vascular Endothelial Growth Factor A; 8001-40-9 / Iodized Oil; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ PMC4305626
  •  go-up   go-down






Advertisement